Results
|
11261.
|
|
|
11262.
|
|
|
11263.
|
|
|
11264.
|
|
|
11265.
|
|
|
11266.
|
L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. [electronic resource] by
- Young, S D
- Britcher, S F
- Tran, L O
- Payne, L S
- Lumma, W C
- Lyle, T A
- Huff, J R
- Anderson, P S
- Olsen, D B
- Carroll, S S
Producer: 19960403
In:
Antimicrobial agents and chemotherapy vol. 39
Availability: No items available.
|
|
11267.
|
|
|
11268.
|
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. [electronic resource] by
- Bassetti, S
- Battegay, M
- Furrer, H
- Rickenbach, M
- Flepp, M
- Kaiser, L
- Telenti, A
- Vernazza, P L
- Bernasconi, E
- Sudre, P
Producer: 19990616
In:
Journal of acquired immune deficiency syndromes (1999) vol. 21
Availability: No items available.
|
|
11269.
|
|
|
11270.
|
|
|
11271.
|
|
|
11272.
|
|
|
11273.
|
Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. [electronic resource] by
- Ross, L
- Scarsella, A
- Raffanti, S
- Henry, K
- Becker, S
- Fisher, R
- Liao, Q
- Hirani, A
- Graham, N
- St Clair, M
- Hernandez, J
Producer: 20011101
In:
AIDS research and human retroviruses vol. 17
Availability: No items available.
|
|
11274.
|
Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). [electronic resource] by
- Pellegrin, Isabelle
- Breilh, Dominique
- Montestruc, François
- Caumont, Anne
- Garrigue, Isabelle
- Morlat, Philippe
- Le Camus, Cécile
- Saux, Marie-Claude
- Fleury, Hervé J A
- Pellegrin, Jean-Luc
Producer: 20030225
In:
AIDS (London, England) vol. 16
Availability: No items available.
|
|
11275.
|
|
|
11276.
|
|
|
11277.
|
|
|
11278.
|
|
|
11279.
|
Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks. [electronic resource] by
- Raines, C P
- Flexner, C
- Sun, E
- Heath-Chiozzi, M
- Lewis, R H
- Fields, C
- Deetz, C
- Apuzzo, L
- Eshleman, S H
- Jackson, J B
- Gallant, J E
Producer: 20010118
In:
Journal of acquired immune deficiency syndromes (1999) vol. 25
Availability: No items available.
|
|
11280.
|
|